A Pivotal Year of Clinical Catalysts for Mirum Pharmaceuticals

Mirum Pharmaceuticals faces pivotal 2026 with key data readouts for Volixibat in PSC and Brelovitug in HDV, set to define its rare liver disease portfolio expansion.

For specialized pharmaceutical companies, the journey from initial commercial success to portfolio expansion represents a critical inflection point. Mirum Pharmaceuticals now enters such a phase, with investor focus shifting squarely to a dense schedule of clinical trial results that will determine its future market access. The coming quarters are poised to serve as potential turning points for the company's valuation.

Strategic Presentations and Commercial Expansion

Investors can expect strategic insights imminently. Management is scheduled to present updates on its development programs at specialized conferences hosted by Barclays and Leerink Partners on March 10th and 11th. These events will set the tone for a year characterized less by commercial updates and more by the clinical validation of its pipeline.

On the commercial front, the EXPAND study, which is investigating the efficacy of its lead product for a broader range of rare liver diseases, is on track to complete patient recruitment in the first half of 2026. Recruitment is also progressing as planned for the VANTAGE study.

High-Stakes Data Readouts on the Horizon

The second quarter of 2026 emerges as a particularly decisive period, hosting two major clinical milestones. The topline results from the VISTAS study in primary sclerosing cholangitis (PSC) for Volixibat are highly anticipated. Success here is viewed as crucial for significantly expanding the therapy's addressable market beyond its current uses.

Running in parallel, the Brelovitug program for Hepatitis Delta Virus (HDV) treatment reaches a key juncture. Interim data from the AZURE-1 study are also expected in Q2 2026. Positive outcomes could pave the way for regulatory submission filings later in the year, opening an additional growth pathway for the company.

The collective data from the PSC and HDV studies will be instrumental in determining whether Mirum can solidify its position as a broadly-based specialist in rare liver diseases.

Current Trading and Key Metrics

Mirum shares are currently trading at €76.00. This price sits approximately 18% below the 52-week high of €92.50, reached on February 25, 2026.

• Previous Close (Thursday): €76.00
• 7-Day Change: -2.56%
• 30-Day Change: -8.98%
• Year-to-Date (YTD) Change: +14.29%
• 52-Week High: €92.50 (25/02/2026)
• Distance from 52-Week High: -17.84%
• 52-Week Low: €55.00 (15/12/2025)
• Distance from 52-Week Low: +38.18%
• 50-Day Moving Average: €79.35
• Distance from 50-Day MA: -4.22%
• RSI (14-day): 56.5
• Volatility (30-day, annualized): 56.67%